Actinium Pharmaceuticals Inc (ATNM)

[GoodGuyBill]

BEWARE!!!!! ATNM AND ZACKS MAY BE TRYING TO UNLOAD SHARES ON UNSUSPECTING INVESTORS...BEWARE!!!!!... On 1/13 ZACKS upgraded ATNM to a #1 BUY. But...a week or so later, ZACKS removed the upgrade article and quietly replaced it with another article (with the same date!), changing the rating to a #3 HOLD without a PR. On ZACKS website it is as if the upgrade article never existed!!!!! IS THIS LEGAL!

UPGRADE ARTICLE: https://finance.yahoo.com/news/actinium-atnm-upgraded-strong-buy-170005032.html

Actinium (ATNM) Upgraded to Strong Buy: Here's Why

Actinium Pharmaceuticals (ATNM) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.

Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for Actinium basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock Prices

The change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

For Actinium, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate Revisions

Empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>>.

Earnings Estimate Revisions for Actinium

For the fiscal year ending December 2019, this cancer drug developer is expected to earn -$0.16 per share, which is a change of 27.3% from the year-ago reported number.

Analysts have been steadily raising their estimates for Actinium. Over the past three months, the Zacks Consensus Estimate for the company has increased 5.6%.

Bottom Line

Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a 'Strong Buy' rating and the next 15% get a 'Buy' rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

The upgrade of Actinium to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Here's the new and downgraded article:

Is Anthem (ANTM) a Great Value Stock Right Now?
Zacks Equity Research January 13, 2020

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.

Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.

Zacks has developed the innovative Style Scores system to highlight stocks with specific traits. For example, value investors will be interested in stocks with great grades in the "Value" category. When paired with a high Zacks Rank, "A" grades in the Value category are among the strongest value stocks on the market today.

Anthem (ANTM - Research Report) is a stock many investors are watching right now. ANTM is currently sporting a Zacks Rank of #2 (Buy) and an A for Value. The stock holds a P/E ratio of 13.47, while its industry has an average P/E of 18.21. ANTM's Forward P/E has been as high as 17.02 and as low as 10.62, with a median of 13.33, all within the past year.

Investors will also notice that ANTM has a PEG ratio of 0.87. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. ANTM's industry currently sports an average PEG of 1.37. Over the past 52 weeks, ANTM's PEG has been as high as 1.30 and as low as 0.76, with a median of 0.91.

Another valuation metric that we should highlight is ANTM's P/B ratio of 2.48. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. ANTM's current P/B looks attractive when compared to its industry's average P/B of 3.75. ANTM's P/B has been as high as 2.88 and as low as 1.90, with a median of 2.37, over the past year.

Finally, investors should note that ANTM has a P/CF ratio of 14.56. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 14.76. ANTM's P/CF has been as high as 17.18 and as low as 11.16, with a median of 14.11, all within the past year.

These are only a few of the key metrics included in Anthem's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, ANTM looks like an impressive value stock at the moment.